CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $1.77B, above the global median of $1.18B
- FinancialsAltman Z-Score 5.5: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
6.23%Above 5Y avg (3.05%)
Annual Rate
CNY 2.29Paid semi-annual
Payout Ratio
57.4%Sustainable
Payback Period
18.0 yr
Last Ex-Dividend
Sep 15, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
11.85BCNY1.77B · vs all stocks (USD)
Trailing P/E
11.81xRevenue (TTM)
2.89BCNY430.86M · vs all stocks (USD)
Profit Margin
33.92%Beta
0.2170xvs all stocks
52-Week Change
-22.59%vs all stocks
Forward Annual Dividend Yield
6.23%vs all stocks
Market Capitalization
11.85BCNY1.77B · vs all stocks (USD)
Enterprise Value
9.25BCNY1.38B · vs all stocks (USD)
Trailing P/E
11.81xForward P/E
8.69xPrice to Sales (TTM)
4.04xPrice to Book (MRQ)
2.94xEnterprise to Revenue
3.21xEnterprise to EBITDA
10.46xGross Margin
93.09%Profit Margin
33.92%Operating Margin
28.87%Return on Assets (TTM)
8.24%Return on Equity (TTM)
21.79%Revenue (TTM)
2.89BCNY430.86M · vs all stocks (USD)
Revenue per Share (TTM)
9.01CNYUpdated Sep 21, 2026Quarterly Revenue Growth
-11.50%Gross Profit (TTM)
2.69BCNY401.76M · vs all stocks (USD)
EBITDA (TTM)
1.25BCNY186.34M · vs all stocks (USD)
Net Income (TTM)
978.57MCNY146.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.80%Operating Cash Flow (TTM)
883.69MCNY131.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
407.79MCNY60.90M · vs all stocks (USD)
Forward Annual Dividend Rate
2.29CNYUpdated Sep 21, 2026Forward Annual Dividend Yield
6.23%vs all stocks
Trailing Annual Dividend Rate
2.02CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
5.50%vs all stocks
5-Year Average Dividend Yield
3.05%vs all stocks
Payout Ratio
57.42%Minority Interest (Equity)
339.05MCNYFY2025 · Dec 31, 2025Revenue
2.98BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
172.47MCNYFY2025 · Dec 31, 2025Gross Profit
2.81BCNYFY2025 · Dec 31, 2025Operating Income
969.91MCNY144.84M · vs all stocks (USD)
Pre-tax Income
1.04BCNYFY2025 · Dec 31, 2025Income Tax Expense
123.64MCNYFY2025 · Dec 31, 2025Net Income
916.98MCNYFY2025 · Dec 31, 2025EBIT
1.05BCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
1.14BCNYFY2025 · Dec 31, 2025Research & Development
74.08MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.68BCNYFY2025 · Dec 31, 2025Other Operating Expenses
37.72MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
80.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
12.57MCNYFY2025 · Dec 31, 2025EPS (Basic)
2.91CNYFY2025 · Dec 31, 2025EPS (Diluted)
2.91CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
322.31MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
322.31MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
916.98MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
20.95MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
704.63MCNYFY2025 · Dec 31, 2025Free Cash Flow
689.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.58BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
916.98MCNYFY2025 · Dec 31, 2025Other Non-cash Items
7.50MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-195.42MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-24.44MCNYFY2025 · Dec 31, 2025Capital Expenditures
-15.61MCNYFY2025 · Dec 31, 2025Purchase of Investments
-5.13BCNYFY2025 · Dec 31, 2025Sale of Investments
4.39BCNYFY2025 · Dec 31, 2025Other Investing Activity
162.48MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-589.07MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
960.04MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-482.04MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-613.53MCNYFY2025 · Dec 31, 2025Other Financing Charges
14.12MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-121.41MCNYFY2025 · Dec 31, 2025Shares Outstanding
322.32MSharesUpdated Sep 21, 2026Float Shares
125.28MSharesUpdated Sep 21, 2026% Held by Insiders
60.64%vs all stocks
% Held by Institutions
3.01%vs all stocks
Total Cash (MRQ)
3.74BCNY558.58M · vs all stocks (USD)
Total Cash per Share (MRQ)
11.75CNYUpdated Sep 21, 2026Total Debt (MRQ)
1.17BCNY174.87M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2772xCurrent Ratio (MRQ)
2.88xBook Value per Share (MRQ)
12.29CNYUpdated Sep 21, 2026Total Assets
6.27BCNY935.91M · vs all stocks (USD)
Total Current Assets
4.64BCNYFY2025 · Dec 31, 2025Total Liabilities
2.13BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.63BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
489.78MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.64BCNYFY2025 · Dec 31, 2025Cash
2.31BCNYFY2025 · Dec 31, 2025Cash Equivalents
20.99MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.33BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.12BCNYFY2025 · Dec 31, 2025Accounts Receivable
694.28MCNYFY2025 · Dec 31, 2025Inventory
181.27MCNYFY2025 · Dec 31, 2025Accounts Payable
39.16MCNYFY2025 · Dec 31, 2025Short-term Debt
801.12MCNYFY2025 · Dec 31, 2025Other Current Liabilities
333.33KCNYFY2025 · Dec 31, 2025Long-term Debt
154.63KCNYFY2025 · Dec 31, 2025Common Stock (Book)
322.32MCNYFY2025 · Dec 31, 2025Retained Earnings
2.50BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
4.14BCNY617.85M · vs all stocks (USD)
52-Week Low
34.80CNYUpdated Sep 21, 202652-Week High
50.93CNYUpdated Sep 21, 202652-Week Change
-22.59%vs all stocks
Beta
0.2170xvs all stocks
50-Day MA
38.50CNYUpdated Sep 21, 2026200-Day MA
40.48CNYUpdated Sep 21, 2026Avg 10-Day Volume
2.21MSharesUpdated Sep 21, 2026Avg 30-Day Volume
4.51MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
3.06CNYUpdated Sep 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How is this stock valued?
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 5.5: safe zoneNotable
Altman Z-Score: 5.50
High structural barrier to entryNotable
Barrier to Entry: 0.65
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $1.77B, above the global median of $1.18BNotable
Market cap (USD): 1,769,810,901.92Global Median: 1,180,223,658.953
Levered free cash flow is $60.9M, above the global median of $18.73MNotable
Levered free cash flow (USD): 60,895,426.446Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow
4DMedical Limited
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Septarna Inc.
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Novavax Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jubilant Pharmova Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Inventisbio Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Astra Industrial Group
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value
Classys Inc.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value
Krafton Inc.
2 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesPrice Below Mean With Profitability And Book Value